CRISPR Therapeutics AG (CRSP) Cash from Investing Activities (2015 - 2026)

CRISPR Therapeutics AG (CRSP) has 12 years of Cash from Investing Activities data on file, last reported at -$410.7 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Investing Activities fell 1979.19% year-over-year to -$410.7 million; the trailing twelve-month figure through Mar 2026 stood at -$422.8 million (down 108.85% YoY), and the FY2025 full-year result was -$31.8 million, up 88.66% from the prior year.
• Cash from Investing Activities retreated to -$410.7 million in Q1 2026, from $37.2 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $216.9 million in Q2 2023 to a low of -$410.7 million in Q1 2026.
• A 5-year average of -$35.7 million and a median of -$56.1 million in 2022 frame the typical range for Cash from Investing Activities.
• Across the five-year window, Cash from Investing Activities jumped 486.87% in 2023 and tumbled 1979.19% in 2026, its largest moves.
• Tracing CRSP's Cash from Investing Activities over 5 years: stood at -$175.5 million in 2022, then soared by 53.6% to -$81.5 million in 2023, then jumped by 229.93% to $105.8 million in 2024, then tumbled by 64.85% to $37.2 million in 2025, then tumbled by 1204.18% to -$410.7 million in 2026.
• Business Quant data shows CRSP's Cash from Investing Activities at -$410.7 million in Q1 2026, $37.2 million in Q4 2025, and -$119.2 million in Q3 2025.